Personalis

Tempus AI has made a takeover offer for Personalis of $16.25 per share (about $1.5 billion). Personalis provides tumor profiling solutions that Moderna and Merck use for personalized mRNA cancer vaccines, boosting its growth potential. The share price recently rose above the bid, fueling speculation of a higher offer or additional suitors. Analysts see limited upside for new entrants but say a revaluation of the growth story is possible. » More on deraktionaer.de

Tempus AI announced the acquisition of Personalis in an all-stock transaction worth about $1.5 billion, with Personalis shareholders to receive $16.25 per share and up to 50% potentially paid in cash. The announcement triggered a decline in TEM’s share price as investors worried about the dilution risk from a large equity deal; the stock is well below its 52-week high. Tempus justifies the purchase by integrating the MRD test NeXT Personal into its precision oncology platform and sees a market opportunity of roughly $20 billion; closing is expected in late 2026/early 2027, creating further uncertainty until integration. » More on de.investing.com

Personalis shares lost about 11% in morning trading, falling to $13.70 after Tempus AI announced a definitive takeover agreement in the form of an all-stock deal valued at roughly $1.5 billion. Shareholders are to receive $16.25 per common share, a premium of only 6% to Friday’s close and below recent analyst targets of $17 and $18. The stock-swap structure (with Tempus having the option to pay up to 50% in cash), the long closing window through end-2026/early-2027, and the remaining required approvals explain the selling pressure and share-price risk for Personalis holders. » More on de.investing.com